胃癌治疗中的ATR-CHK1轴抑制剂
Mateusz Kciuk1, Renata Gruszka1, Marta Aleksandrowicz2
1Department of Molecular Biotechnology and Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Banacha Street 12/16, 90-237 Lodz, Poland.
International journal of molecular sciences
|August 28, 2025
概括
通过向DNA损伤反应途径,ATR-CHK1抑制剂对治疗胃癌具有前景. 这种方法为患有晚期疾病的患者提供了新的治疗策略,特别是与其他治疗相结合时.
科学领域:
- 癌症学
- 分子生物学
- 癌症治疗方法
背景情况:
- 胃癌对全球健康造成重大负担, 晚期病例预后不佳.
- 瘤在DNA损伤反应 (DDR) 途径中表现出脆弱性,包括频繁的TP53突变,ARID1A损失,ATM缺陷和复制压力.
- 这些漏洞使得癌细胞生存依赖ATR-CHK1轴.
研究的目的:
- 对胃癌治疗中ATR和CHK1抑制剂的当前临床和临床前证据进行审查.
- 根据合成致死性和免疫调节来探索这些抑制剂的潜力.
- 讨论治疗失败的抵抗机制和策略.
主要方法:
- 关于ATR/ CHK1抑制剂的现有临床和临床前数据的综合.
- 对胃癌分子脆弱性的分析,重点是DDR途径.
- 对化学疗法,放射疗法和免疫疗法的综合策略进行审查.
主要成果:
- 抑制ATR-CHK1轴是一种有前途的胃癌治疗策略.
- 结合化疗,放射治疗或免疫检查点抑制剂的治疗方案可能会提高疗效.
- 以生物标志物为指导的选择和适应剂量对于优化治疗精度和降低毒性至关重要.
结论:
- ATR-CHK1抑制剂为治疗特定的胃癌子组提供了合理的方法.
- 了解耐药机制是制定有效治疗策略的关键.
- 对于生物标志物定义的患者群体,需要进一步研究和临床整合这些抑制剂.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
259
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
259
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
321
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
321
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
DNA Damage can Stall the Cell Cycle
9.3K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.3K
M-Cdk Drives Transition Into Mitosis
5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K


